News
Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...
2h
HealthDay on MSNMetabolic and Bariatric Surgery Increased in Adolescents From 2021 to 2023Despite the approval of second-generation antiobesity medications, metabolic and bariatric surgery (MBS) use among U.S.
A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.
12h
Lose It! on MSNCan Microdosing a GLP-1 Medication Help You Lose Weight?In fact, you may have gotten more than a few targeted ads on social media from telehealth platforms selling these cheaper GLP ...
In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...
A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...
Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.
Hidden fat stored deep within muscles can significantly raise your risk of heart disease, heart attacks, and heart failure, ...
GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results